6576.TWO Foresee Pharmaceuticals Co Ltd
- Market cap
- TWD 11.3B
- P/E
- 513.6x
- P/B
- 9.04x
- ROE
- 44.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6576.TWO undervalued?
Graham numberThe Graham number of Foresee Pharmaceuticals Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Foresee Pharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Foresee Pharmaceuticals Co Ltd yet.
Foresee Pharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for t…
Full company profileForesee Pharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Foresee Pharmaceuticals Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.7M | 26.0M | 75.2M | 230M | 226M | 302M | 195M | 419M | 431M | 524M |
| Gross Profit | 14.9M | 12.1M | 57.9M | 173M | 175M | 276M | 114M | 240M | 294M | 358M |
| Operating Income | -443M | -545M | -470M | -482M | -527M | -438M | -986M | -1.08B | -862M | -483M |
| EBITDA | -430M | -528M | -430M | -432M | -476M | -387M | -912M | -946M | -785M | 702M |
| Net Income | -443M | -552M | -487M | -511M | -569M | -473M | -1.04B | -1.08B | -883M | 566M |
| EPS | -5.35 | -6.03 | -4.78 | -4.98 | -4.80 | -4.00 | -8.14 | -6.98 | -5.61 | 3.59 |
| Balance Sheet | ||||||||||
| Total Assets | 703M | 625M | 1.01B | 2.10B | 1.64B | 1.30B | 1.86B | 2.16B | 1.31B | 1.86B |
| Total Liabilities | 99.4M | 126M | 113M | 270M | 321M | 393M | 617M | 560M | 381M | 586M |
| Shareholders' Equity | 604M | 499M | 896M | 1.83B | 1.32B | 911M | 1.24B | 1.60B | 930M | 1.27B |
| Cash & Short-term Investments | 453M | 214M | 448M | 1.15B | 871M | 690M | 1.01B | 1.37B | 480M | 878M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -483M | -462M | -448M | -675M | -213M | -233M | -888M | -1.17B | -842M | -304M |
| Capital Expenditure | 17.9M | 14.1M | 86.5M | 28.2M | 7.65M | 58.1M | 46.3M | 156M | 15.5M | 93.0M |
| Free Cash Flow | -547M | -572M | -620M | -703M | -221M | -291M | -934M | -1.33B | -858M | -397M |
| Ratios | ||||||||||
| ROE | -73.5% | -110.6% | -54.4% | -27.9% | -43.1% | -51.9% | -83.3% | -67.6% | -95.0% | 44.5% |
| ROA | -63.1% | -88.3% | -48.3% | -24.3% | -34.7% | -36.2% | -55.7% | -50.1% | -67.4% | 30.5% |
| Net Profit Margin | -1,869.3% | -2,118.3% | -647.9% | -221.6% | -251.9% | -156.8% | -531.3% | -258.2% | -204.8% | 108.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Foresee Pharmaceuticals Co Ltd dividends
Foresee Pharmaceuticals Co Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 818:809 on Jun 1, 2023.
Who owns Foresee Pharmaceuticals Co Ltd
- Insiders 51.36%
- Institutions 1.95%
- Public & others 46.69%
- Shares outstanding 158M
- Free float 100M
Foresee Pharmaceuticals Co Ltd company profile
- Company name
- Foresee Pharmaceuticals Co Ltd
- Ticker
- 6576.TWO
- ISIN
- TW0006576002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No. 19-3, Sanchong Road, Taipei, Taiwan, 115
- Phone
- 886 2 7750 0188
- Website
- foreseepharma.com
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.
Foresee Pharmaceuticals Co Ltd management
4- Dr. Benjamin Chien Ph.D.Founder, CEO & Chairman
- Dr. Yuhua Li Ph.D.Co-founder & CTO
- Dr. Mathieu Boudreau Ph.D.COO & Chief Business Officer
- Dr. Yisheng Lee M.B.A., M.D., Ph.D.Chief Medical Officer & Director